Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 09, 2007. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction notification rather than financial performance.
Material Changes
The filing details a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan, which is notionally held in GSK Ordinary Share ADRs. Consequently, there was an increase in the notional allocation of Ordinary Share ADRs on October 05, 2007, at a price of $54.07 per ADR share for Dr. R G Greig.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the transaction date of October 05, 2007, and the execution price of $54.07 per ADR.
- Confirm the identity of the director involved, Dr. R G Greig.
- Note that this filing does not contain financial results or strategic updates.